Integrated Biosciences, a Redwood City, CA-based synthetic biotechnology company developing therapeutics for age-related diseases, raised $17M in Seed funding.
The round was led by Sutter Hill Ventures with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan.
The company intends to use the funds to accelerate the development of its drug pipeline, further develop its platform, and advance its commercialization efforts.
Led by CEO Felix Wong, and Max Wilson, Integrated Biosciences is a biotechnology company pioneering novel approaches that combine synthetic biology and AI-driven small-molecule drug discovery to produce therapeutics targeting age-related diseases.
This capability enables the company to identify new targets, modulate any biological pathway of interest, and deploy its proprietary AI platform to discover precise and novel small-molecule drug candidates. Having developed the first AI-driven discovery of a structural class of antibiotics last year, the company is now developing a portfolio of preclinical-stage assets to treat multiple age-related diseases.
The company also announced that Keith Loebner, Ph.D. has been appointed to the company’s Board of Directors and that Karl Sylvester, M.D., Uri Alon, Ph.D., and Wendy B. Young, Ph.D. have been appointed as advisors.
FinSMEs
03/10/2024